FOUNDATIONFOCUS™ CDx BRCA
- Cancer Type
- Biopsy Type
- Results Expected
What is FoundationFocus CDx BRCA?
FoundationFocus CDx BRCA is the first FDA-approved companion diagnostic assay for the treatment of ovarian cancer with Rubraca® (rucaparib), a PARP inhibitor therapy for BRCA-mutated ovarian cancer.
Conventional tests look only for germline alterations in blood or saliva. FoundationFocus CDx BRCA analyzes ovarian cancer tumor tissue to detect both germline (inherited) and somatic (acquired) BRCA1/2 mutation types associated with response to PARP inhibitor therapy.1,2
FoundationFocus CDx BRCA
1 in 4
women with ovarian cancer are BRCA+ (positive)
- First FDA-approved Next-Generation Sequencing (NGS) companion diagnostic for Rubraca
- Uncovers more BRCA mutations with a single tissue test
- Can help identify more women 2-5 who may benefit from PARP inhibitor therapy